Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more ...

In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

The following is a summary of “Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

When TLC's "What Not to Wear" premiered in 2003, aspiring fashionistas were introduced to a new queen of personal style: ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.